Home Newsfeeds Evercore ISI Group Maintains Outperform on Equitable Holdings, Lowers Price Target to $41

Evercore ISI Group Maintains Outperform on Equitable Holdings, Lowers Price Target to $41

Evercore ISI Group analyst Thomas Gallagher maintains Equitable Holdings (NYSE:EQH) with a Outperform and lowers the price target from $45 to $41.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Evercore ISI Group analyst Thomas Gallagher maintains Equitable Holdings (NYSE:EQH) with a Outperform and lowers the price target from $45 to $41.

FDA
News

Global Coalition For Adaptive Research, Biohaven, And Vigeo Announce Commencement Of Biohaven’s Troriluzole And Vigeo’s VT1021 In GBM AGILE Trial

By Benzinga Newsdesk

July 6, 1:03 PM

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational

BHVN

HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target

By Benzinga Newsdesk

March 13, 6:17 AM

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price target.

VRNA

Why Is DoorDash Down By 8%? 38 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

July 6, 12:08 PM

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 69.5% to $2.1199 after the company announced it has developed a non-invasive blood sensor designated to alert real-time change in patients' clinical condition.

AHG

10 Short Squeeze Candidates To Watch This Week: Getty, Lannett, AirSculpt And More

By Chris Katje

February 13, 12:23 PM

Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.

AIRS

Evercore ISI Group Maintains Outperform on Equitable Holdings, Lowers Price Target to $41

Related Posts

Global Coalition For Adaptive Research, Biohaven, And Vigeo Announce Commencement Of Biohaven’s Troriluzole And Vigeo’s VT1021 In GBM AGILE Trial

HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target

Why Is DoorDash Down By 8%? 38 Stocks Moving In Wednesday’s Mid-Day Session

10 Short Squeeze Candidates To Watch This Week: Getty, Lannett, AirSculpt And More